2003 Experimental Biology Meeting
Interim Meeting of the AACBNC
Experimental Biology '2003
An informal meeting of the executive committee and
an interim socializer for members are planned for the
AACBNC at EB ’2003 in San Diego on Saturday, April 12.
The Executive Committee will meet from 4:00 - 5:30
pm, and the socializer will be held from 5:30-7:30 pm.  
These functions will be held at the San Diego Marriott
Hotel and Marina.  The Executive Committee will meet
in the Boardroom Foyer at 4:00 pm and then go to
another location.  The socializer will be held in the
Boardroom.  The dates of EB '2003 are Friday, April 11
- Tuesday, April 15, 2003.

The socializer will be sponsored by The Anatomical
Record, a Wiley-Liss publication.  Members are
encouraged to bring their spouse or a guest.
Keynote Address

for the American Association of  Anatomists
at EB '2003

Supported by JEOL USA, Inc.
Organized by Mary J. C. Hendrix, Ph.D.
President-Elect of the AACBNC

"Targeting the Vasculature with Novel Strategies"


Erkki Ruoslahti, M.D., Ph.D.
The Burnham Institute

Erkki Ruoslahti, M.D., Ph.D.
(The Burnham Institute)
Sunday, April 13, 6:30 pm -  7:30 pm,
Room 25BC

"Targeting the Vasculature with Novel Stategies"

Abstract:  We use libraries of phage-displayed peptides
to identify specific changes in the vasculature of
normal tissues and tumors. The results show that the
blood vessels in individual tissues are distinct, tumor
blood vessels differ from normal blood vessels, tumor
lymphatics differ from normal lymphatics, and the
markers of tumor blood vessels and lymphatics are
different.  Phage screening also reveals specific
features in the extracellular matrix of tumor vessels
and tumor stroma.  A set of new tumor-homing
peptides, identified by combining ex vivo screening of
the phage libraries on cell suspensions and in vivo
screening for homing to tumor vasculature, will be
discussed in some detail.  One of the peptides, F3, was
obtained by ex vivo screening on cell suspensions
from the bone marrow, followed by in vivo screening
for tumor homing.  F3 recognizes tumor blood vessels
(Porkka et al., PNAS, 8, 751, 2002), and a small
population of cells in the bone marrow that may
represent endothelial cell precursors.  A screening
done ex vivo for binding to tumor cell suspensions
treated to remove blood vessel endothelial cells and
in vivo for tumor homing yielded a peptide (Lyp-1) that
homes to tumor lymphatics (Laakkonen et al., Nature
Med. 99, 7444, 2002).   Both F3 and Lyp-1 also bind to
the tumor cells. A third peptide, CR, binds to the
extracellular matrix of tumor blood vessels and tumor
stroma (Essler et al., submitted).  Fluorescein
conjugates of the F3 and Lyp-1 peptides home to
tumors after an intravenous injection, accumulating
both in endothelial and tumor cells in the tumors.  The
CR peptide homes to tumor stroma.  The F3 and LyP-1
peptides have the remarkable property of being
transported, along with the fluorescein marker
attached to them, in the nucleus of the target cells.
Thus, these peptides may be particularly suitable for
targeting anti-cancer drugs that act in the nucleus.  
Ongoing studies aim at identifying the cell surface
molecules that serve as receptors for these peptides
and establishing the utility of the peptides in targeted
drug delivery.
Chairpersons' Symposium

for the
American Association of Anatomists
at EB '2003
organized by Fred H. Gage and Stephen W. Carmichael


10:45AM to 12:45PM, Saturday 12 April 2003
Fred H. Gage
Salk Institute
"Neurogenesis in the Adult
Mammalian Brain"

Arturo Alvarez-Buylla
University of California, San Francisco
“New Concepts on the Origins of
Neural Stem Cells”

Stuart A. Lipton
The Burnham Institute, La Jolla
"Transcriptional Control of
Neurogenesis and Apoptosis of Stem

Thomas A. Reh
University of Washington
"Retinal Regeneration: Not Too Late
to Change Your Fate"